TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — research page
US · us-cm-kg/NYSE/TEVA · as of 2026-11-08
Identity and listing
The issuer is TEVA PHARMACEUTICAL INDUSTRIES LTD, listed on the NYSE under ticker TEVA. The ISIN is not on the record, and the LEI is not on the record. The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Israel. The issuer is listed and not halted.
| field | value | source · read date |
|---|---|---|
| name | TEVA PHARMACEUTICAL INDUSTRIES LTD | source · 2026-11-08 |
| exchange | NYSE | source · 2026-11-08 |
| ticker | TEVA | source · 2026-11-08 |
| ISIN | not on the record | |
| LEI | not on the record | |
| security type | Corporate | source · 2026-11-08 |
| segment | not on the record | |
| sector | 2834 Pharmaceutical Preparations | source · 2026-11-08 |
| jurisdiction | Israel | source · 2026-11-08 |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 157 filings in the twelve months to 2026-11-08, across 70 filing days. The median gap between filing days is 3 days, and the latest filing was 2 days before the record date. The latest filing is dated 2026-11-06 and is of type directors_dealings. The NYSE median is 6.0 days for cadence gap, 64.0 filings and 4.0 days latency across 3256 issuers. The 2834 Pharmaceutical Preparations sector median is 6.0 days for cadence gap, 63.0 filings and 4.0 days latency across 526 issuers. The issuer's 157 filings are above the NYSE median of 64.0 and above the sector median of 63.0. Its 3-day median gap is below both the NYSE and sector medians of 6.0 days.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 157 | 3 | 2 |
| exchange median: NYSE (3256 issuers) | 64 | 6 | 4 |
| sector median: 2834 Pharmaceutical Preparations (526 issuers) | 63 | 6 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-06 | directors_dealings | 4 | 4 — 4 |
| 2026-11-06 | directors_dealings | 4 | 4 — 4 |
| 2026-11-05 | regulatory_filing | 144 | 144 |
| 2026-11-04 | regulatory_filing | 144 | 144 |
| 2026-11-03 | results | 8-K | 8-K — FORM 8-K (items 2.02,9.01) |
window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is Kesselman & Kesselman, and its location is not on the record. The record holds no auditor changes.
Events and halts
The record holds a listing on 2026-09-14 and a delisting dated 2026-09-14. No name change is on the record. A domicile change and a segment move are not on the record. The issuer is listed and not halted.
Orderability
The outcome is not determinable because the chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.
rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 15 research houses: Argus Research Company, Barclays, Evercore ISI, Goldman Sachs, H.C Wainwright, Jefferies, JPMorgan, Leader Capital Markets, Leerink Partners, Morningstar, Oppenheimer & Co., Piper Sandler, Scotiabank, USA, TD Securities, and UBS (US).
| research house | analyst | source · read date |
|---|---|---|
| Argus Research Company | Jasper Hellweg | issuer page · 2026-11-11 |
| Barclays | Glen Santangelo | issuer page · 2026-11-11 |
| Evercore ISI | Umer Raffat | issuer page · 2026-11-11 |
| Goldman Sachs | Matt Dellatorre | issuer page · 2026-11-11 |
| H.C Wainwright | Douglas Tsao | issuer page · 2026-11-11 |
| Jefferies | Dennis Ding | issuer page · 2026-11-11 |
| JPMorgan | Christopher T. Schott | issuer page · 2026-11-11 |
| Leader Capital Markets | Sabina Levy | issuer page · 2026-11-11 |
| Leerink Partners | Daniel Clark | issuer page · 2026-11-11 |
| Morningstar | Keonhee Kim | issuer page · 2026-11-11 |
| Oppenheimer & Co. | Les Sulewski | issuer page · 2026-11-11 |
| Piper Sandler | David A. Amsellem | issuer page · 2026-11-11 |
| Scotiabank, USA | Louise Chen | issuer page · 2026-11-11 |
| TD Securities | Joe Thome | issuer page · 2026-11-11 |
| UBS (US) | Ashwani Verma | issuer page · 2026-11-11 |
Open research
No openly published research notes were found.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.
Sources
8 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)
- 10.2
- https://data.sec.gov/submissions/CIK0000818686.json (identity.jurisdiction)
- 10.3
- https://mcp.us-cm-kg.ai/events/NYSE/TEVA (the disclosure lines)
- 10.4
- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)
- 10.5
- https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm (the auditor)
- 10.6
- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.7
- https://ir.tevapharm.com/investor-resources/analyst-coverage/default.aspx (coverage)
- 10.8
- https://mcp.us-cm-kg.ai/record/NYSE/TEVA (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"ticker":"TEVA","exchange":"NYSE"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:23d0c6b084b08a5e.